文献速递血栓与止血

2023年美国风湿病学会/欧洲抗风湿病联盟抗磷脂综合征分类标准在抗磷脂综合征队列中的性能验证

Performance validation of the 2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria in an antiphospholipid syndrome cohort.
PubMed 文献 · J Thromb Haemost · 2024-03-09

该单中心队列研究纳入526例符合2023年标准入门条件的患者,以专家共识小组分类为金标准,比较2023年与2006年悉尼修订标准的敏感性和特异性。2023年标准总体特异性高于2006年标准(0.983 vs 0.950),敏感性相对较低(0.818 vs 0.853),但在系统性红斑狼疮、微血管表现、心脏瓣膜病和血小板减少患者中敏感性改善。

要点

  • 2023年标准总体特异性0.983,高于2006年标准的0.950,敏感性0.818低于2006年的0.853。
  • 在系统性红斑狼疮患者中,2023年标准敏感性0.860,高于2006年标准的0.825。
  • 2023年标准敏感性降低与遗漏部分微血管表现、更严格的妊娠病态定义及排除孤立性血小板减少和孤立性IgM型抗磷脂抗体相关。

核心结论

  • 与2006年标准相比,2023年标准总体特异性更高,并在系统性红斑狼疮、微血管表现、心脏瓣膜病和血小板减少等特定患者亚组中敏感性改善。

研究设计与样本

  • 单中心队列研究,纳入526例符合2023年标准入门条件的患者,以专家共识小组分类为金标准,比较2023年与2006年标准的敏感性和特异性。

主要发现

  • 共纳入526例患者,平均年龄38.55±12.67岁,其中女性366例(69.58%),系统性红斑狼疮182例(34.60%)。
  • 407例(77.38%)患者被专家分类为抗磷脂综合征。
  • 2023年标准总体特异性0.983,高于2006年标准的0.950;敏感性0.818,低于2006年标准的0.853。
  • 在系统性红斑狼疮患者中,2023年标准敏感性0.860,高于2006年标准的0.825;在微血管表现患者中为0.867 vs 0.786;在心脏瓣膜病患者中为0.903 vs 0.774;在血小板减少患者中为0.811 vs 0.790。
  • 2023年标准敏感性降低与遗漏某些微血管表现、更严格的妊娠病态定义、以及将孤立性血小板减少和孤立性IgM型抗磷脂抗体分别排除在临床标准和实验室标准之外有关。

关键数值与推荐

  • 2023年标准总体特异性0.983 vs 2006年标准0.950;敏感性0.818 vs 0.853。
  • 系统性红斑狼疮患者敏感性0.860 vs 0.825;微血管表现患者0.867 vs 0.786;心脏瓣膜病患者0.903 vs 0.774;血小板减少患者0.811 vs 0.790。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2023 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) antiphospholipid syndrome (APS) classification criteria were developed with higher specificity but lower sensitivity compared with the 2006 Sydney revised classification criteria. OBJECTIVES: To validate the performance of the 2023 ACR/EULAR APS classification criteria in a large Chinese APS cohort. METHODS: This was a single-center cohort study. Inclusion criteria aligned with the entry criteria of 2023 criteria. APS classification by "expert consensus panel" served as the gold standard. Sensitivity and specificity were compared between the 2023 and 2006 criteria. RESULTS: A total of 526 patients with a mean age of 38.55 ± 12.67 years were enrolled, of whom 366 (69.58%) were female and 182 (34.60%) had systemic lupus erythematosus (SLE). Among them, 407 (77.38%) patients were classified as APS by experts. The 2023 criteria demonstrated higher overall specificity than the 2006 criteria (0.983 vs 0.950), while sensitivity was relatively lower (0.818 vs 0.853). The sensitivity of the 2023 criteria improved for patients with SLE (0.860 vs 0.825), microvascular manifestations (0.867 vs 0.786), cardiac valve disease (0.903 vs 0.774), and thrombocytopenia (0.811 vs 0.790). Reduced sensitivity of the 2023 criteria was linked to the omission of certain microvascular manifestations, a stricter definition of pregnancy morbidity, and the exclusion of isolated thrombocytopenia and isolated IgM isotype antiphospholipid antibodies from meeting clinical and laboratory criteria, respectively. CONCLUSION: The 2023 criteria offer higher overall specificity and improved sensitivity in specific patient subsets, such as those with SLE, microvascular manifestations, cardiac valve disease, and thrombocytopenia when compared with the 2006 criteria.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Huang C, Zhou Y, et al. Performance validation of the 2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria in an antiphospholipid syndrome cohort. J Thromb Haemost. 2024. PMID: 38462219. doi:10.1016/j.jtha.2024.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。